237 related articles for article (PubMed ID: 29288501)
1. Optimal iodine supplementation during antithyroid drug therapy for Graves' disease is associated with lower recurrence rates than iodine restriction.
Huang H; Shi Y; Liang B; Cai H; Cai Q; Lin R
Clin Endocrinol (Oxf); 2018 Mar; 88(3):473-478. PubMed ID: 29288501
[TBL] [Abstract][Full Text] [Related]
2. Restriction of dietary Iodine does not ameliorate the early effect of anti-thyroid drug therapy for Graves' disease in an area of excessive iodine intake.
Hiraiwa T; Ito M; Imagawa A; Takamatsu J; Kuma K; Miyauchi A; Hanafusa T
J Endocrinol Invest; 2006 Apr; 29(4):380-4. PubMed ID: 16699308
[TBL] [Abstract][Full Text] [Related]
3. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
Glinoer D; de Nayer P; Bex M;
Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
[TBL] [Abstract][Full Text] [Related]
4. When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves' disease be discontinued?
Park S; Song E; Oh HS; Kim M; Jeon MJ; Kim WG; Kim TY; Shong YK; Kim DM; Kim WB
Endocrine; 2019 Aug; 65(2):348-356. PubMed ID: 31236779
[TBL] [Abstract][Full Text] [Related]
5. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease.
Zimmermann-Belsing T; Nygaard B; Rasmussen AK; Feldt-Rasmussen U
Eur J Endocrinol; 2002 Feb; 146(2):173-7. PubMed ID: 11834425
[TBL] [Abstract][Full Text] [Related]
6. The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study.
Kim YA; Cho SW; Choi HS; Moon S; Moon JH; Kim KW; Park DJ; Yi KH; Park YJ; Cho BY
Thyroid; 2017 Apr; 27(4):491-496. PubMed ID: 28001121
[TBL] [Abstract][Full Text] [Related]
7. GENDER INFLUENCES THE CLINICAL PRESENTATION AND LONG-TERM OUTCOME OF GRAVES DISEASE.
Magri F; Zerbini F; Gaiti M; Capelli V; Ragni A; Rotondi M; Chiovato L
Endocr Pract; 2016 Nov; 22(11):1336-1342. PubMed ID: 27540885
[TBL] [Abstract][Full Text] [Related]
8. T4 but not T3 administration is associated with increased recurrence of Graves' disease after successful medical therapy.
Mastorakos G; Doufas AG; Mantzos E; Mantzos J; Koutras DA
J Endocrinol Invest; 2003 Oct; 26(10):979-84. PubMed ID: 14759070
[TBL] [Abstract][Full Text] [Related]
9. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for the Relapse of Graves' Disease Treated With Antithyroid Drugs: A Systematic Review and Meta-analysis.
Shi H; Sheng R; Hu Y; Liu X; Jiang L; Wang Z; Cui D
Clin Ther; 2020 Apr; 42(4):662-675.e4. PubMed ID: 32139177
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease.
Izumi Y; Takeoka K; Amino N
Endocr J; 2005 Aug; 52(4):493-7. PubMed ID: 16127219
[TBL] [Abstract][Full Text] [Related]
12. Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission.
Konishi T; Okamoto Y; Ueda M; Fukuda Y; Harusato I; Tsukamoto Y; Hamada N
Endocr J; 2011; 58(2):95-100. PubMed ID: 21206137
[TBL] [Abstract][Full Text] [Related]
13. Antithyroid drug treatment for graves' disease in children: a long-term retrospective study at a single institution.
Ohye H; Minagawa A; Noh JY; Mukasa K; Kunii Y; Watanabe N; Matsumoto M; Suzuki M; Yoshihara A; Ito K; Ito K
Thyroid; 2014 Feb; 24(2):200-7. PubMed ID: 23926918
[TBL] [Abstract][Full Text] [Related]
14. Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications.
Harvengt J; Boizeau P; Chevenne D; Zenaty D; Paulsen A; Simon D; Guilmin Crepon S; Alberti C; Carel JC; Léger J
Eur J Endocrinol; 2015 Jun; 172(6):715-23. PubMed ID: 25766047
[TBL] [Abstract][Full Text] [Related]
15. [Long-term follow up after antithyroid drug treatment in Graves' disease].
Wille T; Müller B; Noth D; Bürgi U; Diem P
Praxis (Bern 1994); 2006 Jul; 95(29-30):1121-7. PubMed ID: 16916174
[TBL] [Abstract][Full Text] [Related]
16. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
Benker G; Reinwein D; Kahaly G; Tegler L; Alexander WD; Fassbinder J; Hirche H
Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342
[TBL] [Abstract][Full Text] [Related]
17. Excessive iodine intake does not increase the recurrence rate of graves' disease after withdrawal of the antithyroid drug in an iodine-replete area.
Park SM; Cho YY; Joung JY; Sohn SY; Kim SW; Chung JH
Eur Thyroid J; 2015 Mar; 4(1):36-42. PubMed ID: 25960960
[TBL] [Abstract][Full Text] [Related]
18. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.
Kumeda Y; Inaba M; Tahara H; Kurioka Y; Ishikawa T; Morii H; Nishizawa Y
J Clin Endocrinol Metab; 2000 Nov; 85(11):4157-61. PubMed ID: 11095447
[TBL] [Abstract][Full Text] [Related]
19. Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy.
Choi YM; Kwak MK; Hong SM; Hong EG
Endocrinol Metab (Seoul); 2019 Sep; 34(3):268-274. PubMed ID: 31565879
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up result of antithyroid drug treatment of Graves' hyperthyroidism in a large cohort.
Jin M; Jang A; Kim CA; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Eur Thyroid J; 2023 Apr; 12(2):. PubMed ID: 36826832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
